Loss of heterozygosity and microsatellite instabilities of fragile histidine triad gene in gastric carcinoma

Table 1 Primer sequences of FHIT gene at different sites

MSM	Sequence		Product lengh
D3S1300	F	5’-ATAAACACTACAAAGGAAC-3’	49 bp
	R	5’-TATCTTAAAATTGCACCC-3’
D3S1234	F	5’-ACGGTGGACGAGAAGAAC-3’	612 bp
	R	5’-TTTGAACAAGAAGTGGCATA-3’
D3S1481	F	5’-CTGTGGGTTGTCTGTTTA-3’	489 bp
	R	5’-CTGGAGGCATCTCATTAC-3’
D3S4103	F	5’-TGGTTTGGTGCTATTCTC-3’	226 bp
	R	5’-TTATTCGGCTCATTGTTC-3’

MSM : Microsatellite marker.

Table 2 FHIT gene LOH and MSI at different microsatellite sites n (%)

MSM	n	AIT	MSI	LOH
D3S1300	50	38 (76.0)	14 (36.8)	10 (26.3)
D3S1234	50	42 (80.4)	9 (21.4)	13 (31.0)
D3S1481	50	29 (54.5)	6 (20.7)	8 (27.6)
D3S4103	50	39 (74.5)	10 (25.6)	17 (43.6)

MSM: Microsatellite marker; AIT: Analysis information target; MSI: Microsatellite instabilities; LOH: Loss of heterozygosity.

Table 3 Relationship between FHIT gene LOH, MSI and clinicopathological characteristics of gastric cancer n (%)

	n	MSI 1	LOH 2
Histological type
pap.ade & wel.ade	6	3 (50)	4 (66.7)
mod.ade	9	5 (55.6)	5 (55.6)
por.ade	26	13 (50.0)	17 (65.4)
muc.ade	7	3 (42.9)	3 (42.9)
SRC	2	1 (50.0)	1 (50.0)
Lauren
Diffusive type	35	17 (48.6)	21 (60.0)
Intestinal type	15	8 (53.3)	9 (60.0)
Bormann
I	5	3 (60.0)	3 (60.0)
II	10	6 (60.0)	7 (70.0)
III	15	7 (46.7)	10 (66.7)
IV	10	5 (50.0)	7 (70.0)
Invasive depth
without serosa penetration	16	7 (43.8)	6 (37.5)
with serosa penetration	34	18 (52.9)	25 (73.5)a
LN metastasis
+	35	12 (34.3)	21 (60.0)
-	15	10 (66.7)a	9 (60.0)

¹ MSI occurring at least one microsatellite site; ² LOH occurring at least one microsatellite site; ^aP < 0.05 vs without serosa penetration and with LN metastasis.